A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 239
- Registration Number
- NCT01029262
- Locations
- πΊπΈ
Hackensack University Medical Center, Hackensack, New Jersey, United States
π¨π¦Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
πΊπΈSouthern Illinois Hematology Oncology, Centralia, Illinois, United States
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).
- Conditions
- Mantle Cell LymphomaNon-Hodgkin's Lymphoma
- Interventions
- Other: Placebo
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 9
- Registration Number
- NCT01021423
- Locations
- πΊπΈ
Hackensack University Medical Center, Hackensack, New Jersey, United States
πΊπΈFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
πΊπΈIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1059
- Registration Number
- NCT00988208
- Locations
- πΊπΈ
Cookeville Regional Medical Center, Cookeville, Tennessee, United States
πΊπΈVeterans Education and Research Association of Northern New England, Inc., White River Junction, Vermont, United States
π¦πΉMedizinische Universitat Wien, Vienna, Austria
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT00975806
- Locations
- πΊπΈ
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
πΊπΈCleveland Clinic Main Campus, Cleveland, Ohio, United States
πΊπΈTennessee Oncology, Nashville, Tennessee, United States
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Relapsed or Refractory Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Celgene
- Target Recruit Count
- 104
- Registration Number
- NCT00963105
- Locations
- πΊπΈ
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States
πΊπΈCancer Center of Central Connecticut, Southington, Connecticut, United States
π¨π¦Cross Cancer Institute, Edmonton, Alberta, Canada
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 25
- Registration Number
- NCT00928486
- Locations
- π―π΅
Nagoya Medical Center, Nagoya-city, Aichi, Japan
π―π΅Niigata Cancer Center Hospital, Niigata-city, Niigata, Japan
π―π΅Keio University Hospital, Tokyo, Japan
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT00915083
- Locations
- πΊπΈ
James Graham Brown Cancer Center, Louisville, Kentucky, United States
πΊπΈSarcoma Oncology Center, Santa Monica, California, United States
πΊπΈSinai Hospital of Baltimore- Alvin and Lois Lapidus Cancer Institute, Baltimore, Maryland, United States
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
- Conditions
- Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00910858
- Locations
- πΊπΈ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
- Conditions
- B-Cell Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 450
- Registration Number
- NCT00910910
- Locations
- πΊπΈ
Drexel University, College of Medicine, Philadelphia, Pennsylvania, United States
π§πͺHopital de Jolimont, Haine-Saint Paul, Belgium
π§πͺCHU Mont -Godinne, Yvoir, Belgium
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Conditions
- Mantle Cell LymphomaLymphoma, Mantle-Cell
- Interventions
- Drug: Investigators choice single agent
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 254
- Registration Number
- NCT00875667
- Locations
- π΅π±
Malopolskie Centrum medyczne s.c., KrakΓ³w, Poland
π³π±Isala Klinieken, Zwolle, Netherlands
π§πͺUZ Brussels, Brussel, Belgium